Fleebs-Logo
Details werden geladen...

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome | The Manila Times

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company’s Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).

Ähnliche Seiten

https://www.manilatimes.net/2026/06/13/tmt-newswire/globenewswire/rhythm-pharmaceuticals-presents-positive-interim-six-month-data-from-phase-2-trial-of-setmelanotide-in-patients-with-prader-willi-syndrome-pws-at-endo-2026/2364858

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 | The Manila Times

https://www.manilatimes.net/2026/06/13/tmt-newswire/globenewswire/rhythm-pharmaceuticals-presents-positive-interim-six-month-data-from-phase-2-trial-of-setmelanotide-in-patients-with-prader-willi-syndrome-pws-at-endo-2026/2364858
https://www.manilatimes.net/2026/05/29/tmt-newswire/globenewswire/rhythm-pharmaceuticals-announces-seven-abstracts-accepted-for-presentation-at-endo-2026/2354510

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026 | The Manila Times

https://www.manilatimes.net/2026/05/29/tmt-newswire/globenewswire/rhythm-pharmaceuticals-announces-seven-abstracts-accepted-for-presentation-at-endo-2026/2354510
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/tenaya-therapeutics-to-announce-new-interim-data-from-mypeak-1-phase-1b2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026/2357329

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 | The Manila Times

https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/tenaya-therapeutics-to-announce-new-interim-data-from-mypeak-1-phase-1b2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026/2357329
https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/orion-pharma-announces-first-results-from-phase-12-teades-trial-with-tead-inhibitor-odm-212-in-patients-with-advanced-solid-tumours/2355072

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours | The Manila Times

https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/orion-pharma-announces-first-results-from-phase-12-teades-trial-with-tead-inhibitor-odm-212-in-patients-with-advanced-solid-tumours/2355072
https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/ambros-therapeutics-announces-first-patient-dosed-in-pivotal-crps-rise-phase-3-clinical-trial-of-neridronate-in-patients-with-complex-regional-pain-syndrome-type-1/2360811

Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1 | The Manila Times

https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/ambros-therapeutics-announces-first-patient-dosed-in-pivotal-crps-rise-phase-3-clinical-trial-of-neridronate-in-patients-with-complex-regional-pain-syndrome-type-1/2360811
https://www.manilatimes.net/2026/05/29/tmt-newswire/globenewswire/agios-provides-update-on-phase-2b-trial-of-tebapivat-in-lower-risk-myelodysplastic-syndromes/2354461

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes | The Manila Times

https://www.manilatimes.net/2026/05/29/tmt-newswire/globenewswire/agios-provides-update-on-phase-2b-trial-of-tebapivat-in-lower-risk-myelodysplastic-syndromes/2354461